Published in Medical Letter on the CDC and FDA, September 6th, 2009
The NDA submission was based primarily on data from a Phase III study demonstrating noninferiority to Mycelex Troche (clotrimazole)* in the complete...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.